Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCE: One vs Twice Daily Cardiovascular Agents in Ischemic Heart Disease
NCT04148820Phase 4Unknown
- Sponsor
- Sapienza University of Rome
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin, atorvastatin and perindopril in ischemic heart disease (IHD) (2 arms), sponsored by Sapienza University of Rome. Primary endpoint: Major Adverse Outcome Event at 1 year. Status: unknown.
02
Drugs
aspirinatorvastatinperindopril
03
Conditions
ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT04148820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148820.